Artivion, Inc.

What they do

Artivion manufactures and distributes medical devices and implantable human tissues for cardiac and vascular surgical procedures treating aortic disease. Its four major product families are aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues. The company operates in two reportable segments: Medical Devices and Preservation Services. Medical Devices includes aortic stent grafts, surgical sealants, On-X products, and other products; Preservation Services provides preservation of cardiac and vascular tissues.

Revenue drivers

• Aortic stent grafts — Largest product line, generating $46.4 million in Q2 2026 (37% of total revenue), up 16% year-over-year; includes E-vita, NEXUS, AMDS, and abdominal stent grafts.
• On-X mechanical heart valves — Second-largest product line, generating $30.5 million in Q2 2026 (24% of total revenue), up 19% year-over-year.
• Surgical sealants (BioGlue) — Generates $19.3 million in Q2 2026 (15% of total revenue), flat year-over-year.
• Preservation services — Generates $25.9 million in Q2 2026 (21% of total revenue), up 1% year-over-year; includes tissue preservation services.

Recent performance

Second quarter 2026 revenue was $125.8 million, up 11% on a GAAP basis and 9% on a constant currency basis year-over-year. Net loss for Q2 2026 was $(13.5) million, or $(0.28) per diluted share, compared to net income of $1.3 million in Q2 2025. Adjusted EBITDA was $26.4 million, up 7% from $24.8 million in the prior-year quarter. For the six months ended June 30, 2026, revenue was $242.1 million, up 14% year-over-year. Full-year 2025 revenue was $441.3 million, with net income of $9.8 million.

Strategy

Strategic plan focuses on four growth areas: new products, new indications, global expansion, and business development. In Q2 2026, Artivion completed the acquisition of Endospan Ltd. and its NEXUS Aortic Arch Stent Graft System, and received FDA PMA approval for the AMDS Hybrid Prosthesis. Management states these milestones complete a three-pronged aortic arch portfolio, positioning the company as the only global provider with a complete set of aortic arch solutions. The company is also developing NEXUS as a platform for three additional PMA programs. Global expansion includes entering emerging markets such as China and Brazil.

Risks

• Competition from larger firms — Many competitors have greater financial and personnel resources, which could pressure pricing and market share.
• Regulatory and certification transitions — Transition to the European Medical Device Regulation and renewal of CE Marks could disrupt product supply and customer ordering patterns.
• Supply chain concentration — Dependence on single and sole source suppliers and third-party manufacturing partners poses disruption risk.
• Cybersecurity incident aftermath — The 2024 cybersecurity incident and ongoing threat environment could have adverse effects on business operations and expenses.

Outlook

Management reiterates full-year 2026 revenue guidance of $480–$496 million, representing 7%–11% growth on an adjusted constant currency basis compared to 2025. Adjusted EBITDA is expected to be $92–$99 million, including approximately $8 million of expense related to the Endospan acquisition. Currency is expected to be a tailwind of roughly one percentage point for the full year. Management expressed confidence in achieving this guidance, citing acceleration in stent graft revenue and the AMDS PMA approval.